

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended March 31, 2026

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File Number: 001-39539

**PMV PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)  
**400 Alexander Park Drive, Suite 301**  
**Princeton, NJ**  
(Address of principal executive offices)

**46-3218129**  
(I.R.S. Employer  
Identification No.)

**08540**  
(Zip Code)

**Registrant's telephone number, including area code: (609) 642-6670**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.00001	PMVP	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes  No

As of May 12, 2026, the registrant had 53,331,766 shares of common stock, \$0.00001 par value per share, outstanding.

## Table of Contents

	<u>Page</u>
<b>PART I.</b>	
	1
<b>FINANCIAL INFORMATION</b>	
Item 1.	1
<a href="#">Condensed Consolidated Financial Statements (Unaudited)</a>	1
<a href="#">Condensed Consolidated Balance Sheets (Unaudited)</a>	1
<a href="#">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</a>	2
<a href="#">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</a>	3
<a href="#">Condensed Consolidated Statements of Cash Flows (Unaudited)</a>	4
<a href="#">Notes to Unaudited Condensed Consolidated Financial Statements</a>	5
Item 2.	16
<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	16
Item 3.	23
<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	23
Item 4.	23
<a href="#">Controls and Procedures</a>	23
<b>PART II.</b>	
	24
<b>OTHER INFORMATION</b>	
Item 1.	24
<a href="#">Legal Proceedings</a>	24
Item 1A.	24
<a href="#">Risk Factors</a>	24
Item 2.	24
<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	24
Item 3.	24
<a href="#">Defaults Upon Senior Securities</a>	24
Item 4.	24
<a href="#">Mine Safety Disclosures</a>	24
Item 5.	24
<a href="#">Other Information</a>	24
Item 6.	25
<a href="#">Exhibits</a>	25
<a href="#">Signatures</a>	26

## SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy and approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

- our financial performance;
- the sufficiency of our existing cash, cash equivalents, and marketable securities to fund our future operating expenses and capital expenditure requirements;
- our need to raise additional funding before we can expect to generate any revenues from product sales;
- our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved;
- the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- our anticipated use of our existing cash, cash equivalents, and marketable securities and any proceeds from the ATM Program (as defined below);
- the implementation of our strategic plans for our business and product candidates;
- the size of the market opportunity for our product candidates and our ability to maximize those opportunities;
- the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and investigational new drug applications, or IND, and other regulatory submissions;
- the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;
- our estimates of the number of patients for each of our programs including patients expected to have certain p53 mutations and the number of patients that will enroll in our clinical trials;
- the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results;
- our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated;
- the timing, progress and focus of our clinical trials, and the reporting of data from those trials;
- our ability to obtain and maintain regulatory approval of our product candidates;
- our plans relating to commercializing our product candidates, if approved;
- the expected benefits of our existing and any potential future strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;
- the success of competing therapies that are or may become available;
- the timing or likelihood of regulatory filings and approvals, including our expectation to seek accelerated reviews or special designations, such as breakthrough therapy and orphan drug designation, for our product candidates,

- including our intention to seek accelerated approval for rezatapopt, our lead product candidate, for a tumor-agnostic indication;
- our plans relating to the further development and manufacturing of our product candidates, including for additional indications that we may pursue;
  - existing regulations and regulatory developments in the United States and other jurisdictions;
  - our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;
  - our plans to rely on third parties to conduct and support preclinical and clinical development;
  - our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel; and
  - the impact of geopolitical tensions, such as the Ukraine-Russia war and the conflict in the Middle East, the impact of other disruptions resulting from public health epidemics, macroeconomic events such as future changes in trade regulations, tariff structures, global supply chain challenges, elevated inflation and interest rates and monetary policy changes (including the impact of changes to U.S. federal income tax law), instability in the global banking system, or other related disruptions on our business and the execution of our clinical trials.

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the United States Securities and Exchange Commission on March 6, 2026, as well as in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited).

**PMV Pharmaceuticals, Inc.**  
**Condensed Consolidated Balance Sheets**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

	March 31, 2026	December 31, 2025
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 39,130	\$ 37,983
Marketable securities, current	54,419	74,960
Prepaid expenses and other current assets	2,231	2,284
Total current assets	95,780	115,227
Property and equipment, net	203	237
Right-of-use assets	283	801
Other assets	296	297
Total assets	<u>\$ 96,562</u>	<u>\$ 116,562</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 1,631	\$ 3,155
Accrued expenses	6,671	7,857
Operating lease liabilities, current	293	403
Total current liabilities	8,595	11,415
Operating lease liabilities, noncurrent	—	435
Total liabilities	<u>8,595</u>	<u>11,850</u>
Commitments and contingencies (see Note 6)		
Stockholders' equity:		
Preferred stock, \$0.00001 par value, 5,000,000 shares authorized at March 31, 2026 and December 31, 2025. No shares issued or outstanding at March 31, 2026 and December 31, 2025.	—	—
Common stock, \$0.00001 par value, 1,000,000,000 shares authorized; 53,331,766 and 53,331,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.	—	—
Additional paid-in capital	552,474	551,082
Accumulated deficit	(464,492)	(446,454)
Accumulated other comprehensive income	(15)	84
Total stockholders' equity	87,967	104,712
Total liabilities and stockholders' equity	<u>\$ 96,562</u>	<u>\$ 116,562</u>

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

**PMV Pharmaceuticals, Inc.**  
**Condensed Consolidated Statements of Operations and Comprehensive Loss**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

	<b>Three Months Ended March 31,</b>	
	<b>2026</b>	<b>2025</b>
Operating expenses:		
Research and development	\$ 15,330	\$ 17,441
General and administrative	3,689	4,123
Total operating expenses	19,019	21,564
Loss from operations	(19,019)	(21,564)
Other income (expense):		
Interest income, net	980	1,935
Other income (expense), net	1	(4)
Total other income	981	1,931
Loss before (benefit) provision for income taxes	(18,038)	(19,633)
(Benefit) provision for income taxes	—	(2,197)
Net loss	(18,038)	(17,436)
Unrealized loss on available for sale investments, net of tax	(101)	(62)
Foreign currency translation gain	2	7
Total other comprehensive loss	(99)	(55)
Total comprehensive loss	\$ (18,137)	\$ (17,491)
Net loss per share -- basic and diluted	\$ (0.34)	\$ (0.34)
Weighted-average common shares outstanding	53,331,766	51,952,062

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

**PMV Pharmaceuticals, Inc.**  
**Condensed Consolidated Statements of Stockholders' Equity (Deficit)**  
**(unaudited)**  
**(in thousands, except share amounts)**

	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount				
Balance at December 31, 2024	51,935,134	\$ —	\$ 544,653	\$ 139	\$ (368,712)	\$ 176,080
Exercise of stock options	19,001	—	10	—	—	10
Stock-based compensation expense	—	—	1,508	—	—	1,508
Net loss	—	—	—	—	(17,436)	(17,436)
Unrealized loss on available for sale investments	—	—	—	(62)	—	(62)
Foreign currency translation gain	—	—	—	7	—	7
Balance at March 31, 2025	51,954,135	\$ —	\$ 546,171	\$ 84	\$ (386,148)	\$ 160,107

	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount				
Balance at December 31, 2025	53,331,766	\$ —	\$ 551,082	\$ 84	\$ (446,454)	\$ 104,712
Stock-based compensation expense	—	—	1,392	—	—	1,392
Net loss	—	—	—	—	(18,038)	(18,038)
Unrealized loss on available for sale investments	—	—	—	(101)	—	(101)
Foreign currency translation gain	—	—	—	2	—	2
Balance at March 31, 2026	53,331,766	\$ —	\$ 552,474	\$ (15)	\$ (464,492)	\$ 87,967

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

**PMV Pharmaceuticals, Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
**(unaudited)**  
**(in thousands)**

	<b>Three Months Ended March 31,</b>	
	<b>2026</b>	<b>2025</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (18,038)	\$ (17,436)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation expense	1,392	1,508
Depreciation	34	37
Accretion of discounts on marketable securities	(385)	(840)
Non cash lease income	(2)	(2)
Gain on termination of lease, net	(24)	—
Loss on sales and disposals of fixed assets, net	—	4
Other, net	1	(2)
Change in operating assets and liabilities:		
Prepaid expenses and other assets	53	3,088
Accounts payable	(1,524)	(2,986)
Accrued expenses	(1,186)	(1,637)
Net cash used in operating activities	<u>(19,679)</u>	<u>(18,266)</u>
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	—	(4)
Purchases of marketable securities	(10,676)	(15,727)
Maturities of marketable securities	31,500	44,445
Net cash provided by investing activities	<u>20,824</u>	<u>28,714</u>
<b>Cash flows from financing activities:</b>		
Proceeds from the exercise of stock options	—	10
Net cash provided by financing activities	<u>—</u>	<u>10</u>
Impact of exchange rates on cash, cash equivalents, and restricted cash	2	7
Net increase in cash and cash equivalents	1,147	10,465
<b>Cash, cash equivalents, and restricted cash</b>		
Cash, cash equivalents, and restricted cash - beginning of period	37,983	40,876
Cash, cash equivalents, and restricted cash - end of period	<u>\$ 39,130</u>	<u>\$ 51,341</u>

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

**1. Formation and Business of the Company**

***Organization and Liquidity***

PMV Pharmaceuticals, Inc. (the “Company”) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s headquarters are located at 400 Alexander Park Drive, Suite 301, Princeton, New Jersey.

The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The Company has incurred net losses and negative cash flows from operations since its inception. During the three months ended March 31, 2026, the Company incurred a net loss of \$18,038. For the three months ended March 31, 2026, the Company used \$19,679 of cash for operations. At March 31, 2026, the Company had an accumulated deficit of \$464,492. Cash, cash equivalents, and marketable securities were \$93,549 as of March 31, 2026. Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs. The Company believes it has adequate cash, cash equivalents, and marketable securities to operate for the next 12 months from the date of issuance of these condensed consolidated financial statements.

**2. Summary of Significant Accounting Policies**

The Company’s significant accounting policies are disclosed in the audited condensed consolidated financial statements for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 6, 2026. Since the date of those condensed consolidated financial statements, there have been no changes to its significant accounting policies.

***Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of March 31, 2026, the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of stockholders’ equity, and condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025, are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for any interim period are not necessarily indicative of results for the year ending December 31, 2026, or for any other subsequent interim period. The condensed consolidated balance sheet as of December 31, 2025, has been derived from the Company’s audited condensed consolidated financial statements.

The accompanying condensed consolidated financial statements include the Company’s accounts and the accounts of its wholly owned subsidiary, PMV Pharma Australia Pvt Ltd. All significant intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are presented in United States (“U.S.”) Dollars, which is also the functional currency of the Company.

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

***Use of Estimates***

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and stock-based compensation. Actual results could differ materially from those estimates.

***Fair Value of Financial Instruments***

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

- Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
- Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

***Cash, Cash Equivalents, and Marketable Securities***

Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

The Company's marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument's underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company's marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders' equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the three months ended March 31, 2026 and 2025, the Company recorded \$385 and \$840 of accretion, respectively.

***Property and Equipment***

Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease. Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

***Comprehensive Loss and Accumulated Other Comprehensive Income (Loss)***

Other comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation gains and losses.

***Leases***

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset's economic benefits. The Company determines the initial classification and measurement of its operating right-of-use ("ROU") assets and operating lease liabilities at the lease commencement date, and thereafter if modified. The lease term includes any renewal options that the Company is reasonably certain to exercise. The Company's policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company's only existing lease recorded on the balance sheet is for office space.

The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.

Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.

Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company's share of the lessor's operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company's leases contain residual value guarantees.

The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

***Concentration of Credit Risk and Other Risks and Uncertainties***

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash and cash equivalents were held at primarily two financial institutions. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company's marketable securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company's product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.

***Recently Adopted Accounting Pronouncements***

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

reconciliation and additional information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) are equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for annual periods beginning after December 15, 2024. The Company adopted this guidance prospectively for the annual period ending December 31, 2025. For additional information, see “Note 9 — Income Taxes.”

***Recent Accounting Pronouncements Not Yet Adopted***

In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”. This amended guidance requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard becomes effective for reporting companies with annual reporting periods beginning after December 15, 2026, and requires prospective application with an option to apply it retrospectively. The Company anticipates adopting this standard in its Annual Report on Form 10-K for the year ending December 31, 2027. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

In September 2025, the FASB issued ASU 2025-07 (“ASU 2025-07”), Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The guidance refines the scope of Topic 815 to clarify which contracts are subject to derivative accounting. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The amendments in ASU 2025-07 are effective for fiscal years beginning after December 15, 2026, and interim reporting periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.

**3. Fair Value Measurements**

The Company’s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. Cash and cash equivalents includes money market funds and certain corporate securities, which are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Marketable securities are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1. There were no Level 3 assets or liabilities at March 31, 2026.

The following tables show the Company’s cash equivalents and available-for-sale securities’ carrying amounts and fair values as of March 31, 2026, and December 31, 2025:

	As of March 31, 2026						
	Carrying Amount	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Quoted price in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Financial assets</b>							
Money market funds	\$ 36,053	\$ —	\$ —	\$ 36,053	\$ 36,053	\$ —	\$ —
Corporate securities	26,991	2	(44)	26,949	—	26,949	—
Government securities	30,438	25	(7)	30,456	30,456	—	—
<b>Total financial assets</b>	<b>\$ 93,482</b>	<b>\$ 27</b>	<b>\$ (51)</b>	<b>\$ 93,458</b>	<b>\$ 66,509</b>	<b>\$ 26,949</b>	<b>\$ —</b>

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

As of December 31, 2025							
	Carrying Amount	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Quoted Price in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservab le Inputs (Level 3)
<b>Financial assets</b>							
Money market funds	\$ 29,909	\$ —	\$ —	\$ 29,909	\$ 29,909	\$ —	\$ —
Corporate securities	30,636	12	(4)	30,644	—	30,644	—
Government securities	52,229	68	—	52,297	52,297	—	—
Total financial assets	\$ 112,774	\$ 80	\$ (4)	\$ 112,850	\$ 82,206	\$ 30,644	\$ —

**Cash and Cash Equivalents** — As of March 31, 2026, the Company had aggregate cash and cash equivalents of \$39,130, including cash equivalents of \$39,039, consisting of \$36,053 of money market funds and \$2,986 of corporate securities. As of December 31, 2025, the Company had aggregate cash and cash equivalents of \$37,983, including cash equivalents of \$37,890 consisting of \$29,909 of money market funds and \$7,981 of corporate securities.

**Marketable Securities** — Marketable securities of \$54,419 as of March 31, 2026, consisted of corporate debt securities of \$23,963 and government debt securities of \$30,456. There were \$54,419 current marketable securities and no noncurrent marketable securities as of March 31, 2026. Marketable securities of \$74,960 as of December 31, 2025, consisted of corporate debt securities of \$22,663 and government debt securities of \$52,298. There were \$74,960 current marketable securities and no noncurrent marketable securities as of December 31, 2025.

As of March 31, 2026, and December 31, 2025, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded.

**4. Property and Equipment, Net**

	March 31, 2026	December 31, 2025
Machinery & equipment	\$ 1,447	\$ 1,447
Computers	13	13
Furniture & fixtures	23	23
Leasehold improvements	80	81
Total property and equipment	1,563	1,564
Less: Accumulated depreciation	(1,360)	(1,327)
Property and equipment, net	\$ 203	\$ 237

Depreciation expense for the three months ended March 31, 2026 and 2025, was \$34 and \$37, respectively.

**5. Accrued Expenses**

Accrued expenses consist of the following:

	March 31, 2026	December 31, 2025
Accrued compensation	\$ 2,415	\$ 4,532
Accrued research and development costs	4,140	3,130
Accrued legal and professional services	116	195
Total	\$ 6,671	\$ 7,857

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

**6. Commitments and Contingencies**

**Operating Leases**

In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space (the “One Research Way Lease”) at One Research Way in Princeton, New Jersey (the “Premises”). The lease term initially extended through 2032, had a five-year extension option, and replaced the Company’s two prior facilities as the Company’s headquarters in March 2023. The Company estimated that payments under the One Research Way Lease would be \$19,889 through May 2032. The Company received a lease incentive of \$4,046 from the lessor for a buildout of laboratory, vivarium, and office space. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. Since the inception date of the lease, \$4,046 reimbursements were received from the lessor.

In August 2024, the Company entered into a Lease Termination Agreement with BMR-One Research Way LLC (the “Landlord”), in connection with the termination of the One Research Way Lease (the “Termination Agreement”). The Termination Agreement was contingent on the sale of the Premises by the Landlord to a prospective new buyer, which was met on October 1, 2024, and, as a result, there was no modification in August 2024.

Pursuant to the Termination Agreement, the Company surrendered the Premises in October 2024 and paid a total termination fee of approximately \$1,420, consisting of (i) a cash payment in the amount of approximately \$798 and (ii) a release of a security deposit from the Company’s existing letter of credit in the amount of approximately \$622. The transaction was accounted for as an immediate termination of an operating lease before the expiration of the lease term in accordance with ASC 842. The Company derecognized the lease-related asset and liability resulting in a gain of \$4,850. Since the termination fee of \$1,420 was not already included in the lease payments, the termination fee was recognized as a loss on termination of the lease. Further, the Company abandoned and wrote-off all the related leasehold improvements totaling \$9,454 held at the Premises. This net activity totaling \$6,024 was recorded as a loss within General and Administrative expense in the Statement of Operations for the year ended December 31, 2024.

In August 2024, the Company signed a sublease for 14,201 square feet of office space at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey, to be used as its new headquarters (the “400 Alexander Sublease”). The 400 Alexander Sublease commenced on October 1, 2024 and extends until February 28, 2027. Payment under the 400 Alexander Sublease will total \$789 through February 2027.

In September 2024, the Company signed a sublease agreement for 3,205 square feet of office and laboratory space at 311 Pennington Rocky Hill Road in Hopewell, New Jersey (the “311 Pennington Sublease”). The Company utilizes the premises as laboratory space for research and development activities. The term of the 311 Pennington Sublease extended through 2029 and provided the Company with the option to extend the term for an additional three year period. Payment under the 311 Pennington Sublease totaled \$192 through February 2026.

In March 2026, the 311 Pennington Sublease was terminated effective March 4, 2026, upon the termination of the primary lease between the master landlord and the tenant, in accordance with the terms of the sublease agreement. As a result, the Company accounted for the 311 Pennington Sublease termination as an immediate termination of an operating lease before the expiration of the lease term in accordance with ASC 842. Upon termination, the Company derecognized the related operating lease right-of-use asset and lease liabilities and recorded a net gain of approximately \$24, which was recognized in General and Administrative expense in the accompanying Statement of Operations for the three months ended March 31, 2026.

The components of lease cost for the three months ended March 31, 2026 and 2025, were as follows:

	Three Months Ended March 31,	
	2026	2025
Operating lease cost	\$ 106	\$ 118
Variable lease cost	20	17
Short-term lease cost	25	—
Total lease cost	<u>\$ 151</u>	<u>\$ 135</u>

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

Amounts reported in the balance sheet for leases where the Company is the lessee as of March 31, 2026, and December 31, 2025, were as follows:

Operating Leases (in thousands, except lease term and discount rate data):	March 31, 2026	December 31, 2025
Right-of-use assets, operating leases	\$ 283	\$ 801
Operating lease liabilities, current	\$ 293	\$ 403
Operating lease liabilities, non-current	—	435
Total operating lease liabilities	\$ 293	\$ 838
Weighted-average remaining lease term (years)	0.92	2.76
Weighted-average discount rate	13.70%	13.70%

Other information related to leases for the three months ended March 31, 2026 and 2025, respectively, were as follows:

	Three Months Ended March 31,	
	2026	2025
Net cash paid for amounts included in the measurement of lease liabilities	\$ 109	\$ 203
Leased assets (derecognized) in exchange for new or modified operating lease liabilities	(432)	(84)

Future minimum lease payments, net of reimbursements, remaining as of March 31, 2026, under operating leases by fiscal year were as follows:

Fiscal year	(in thousands)
2026	253
2027	56
2028	—
2029	—
Thereafter	—
Total lease payments	\$ 309
Less: Present Value Adjustment	(16)
Present value of lease payments	\$ 293

Rent expense recorded during the three months ended March 31, 2026 and 2025 was \$131 and \$118, respectively.

**Contingencies**

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

**7. Stockholders' Equity**

The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of \$0.00001 per share and 5,000,000 shares of preferred stock with a par value of \$0.00001 per share. At March 31, 2026 and December 31, 2025, there were 53,331,766 and 53,331,766 shares of common stock issued and outstanding, respectively.

Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders. As of March 31, 2026, no dividends on common stock had been declared by the Company.

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

***ATM Program***

On October 4, 2021, the Company entered into an at-the-market offering program (the “ATM Program”). Pursuant to the ATM Program, the Company may offer and sell shares of its common stock having aggregate gross sales proceeds of up to \$150.0 million from time to time. During the three months ended March 31, 2026, the Company did not sell any shares of its common stock under the ATM Program. As of March 31, 2026, the Company had approximately \$113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

**8. Stock Plan**

***2020 Equity Incentive Plan***

The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on September 24, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was 4,406,374, which shall be increased, upon approval by the Company’s board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of common stock, (ii) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2026, the board’s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (ii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by 2,666,470 shares, effective as of January 1, 2026. As of March 31, 2026, there were 3,358,305 shares available for issuance under the 2020 Plan.

On January 18, 2024, the Company granted 952,665 Restricted Stock Units (“RSUs”) to employees VP-level or higher, pursuant to an employee retention program approved by the compensation committee of the Company’s board of directors. As of March 31, 2026 such RSUs were fully vested and common stock was issued upon settlement of the RSUs. As of March 31, 2026, no RSUs awards were granted, vested, or unvested.

***2020 Employee Stock Purchase Plan***

The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on September 24, 2020. A total of 400,752 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the Company’s board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2026, the Company’s board of directors waived the annual increase to the shares reserved under the 2020 ESPP. As of March 31, 2026, 611,415 shares are issued or outstanding, and there were 1,162,196 shares available for issuance, under the 2020 ESPP.

***Stock Options***

On July 16, 2024, the Company filed with the Securities and Exchange Commission a Tender Offer Statement on Schedule TO defining the terms and conditions of a one-time voluntary stock option exchange to its employees of certain options to purchase up to an aggregate of 2,820,491 shares of the Company’s common stock (the “Option Exchange”). On August 13, 2024, the completion date of the Option Exchange, stock options covering an aggregate of 2,786,691 shares of common stock were tendered by eligible employees, and the Company granted new options at an exercise price of \$1.48, the Company’s closing stock price on August 13, 2024, covering an aggregate of 2,786,691 shares of common stock under the 2020 Plan in exchange for the tendered options. The new options are subject to a new three or four-year vesting schedule, vesting in equal annual installments over the vesting term. Each new option has a maximum term of ten years. The Option Exchange was treated as a modification for accounting purposes. As a result of the Option Exchange, the Company will recognize incremental stock-based compensation expense of \$1,370 over the requisite service period of the new stock options, which is three or four years. The Company will recognize the sum of the incremental stock-based compensation expense and the remaining unrecognized compensation expense for the original awards on the modification date, over the requisite service period of the new stock options.

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

The following table summarizes option activity for the three-month period ended March 31, 2026:

	Options Outstanding			
	Number of Options	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in 000s)
<b>Balances at December 31, 2025</b>	11,990,688	\$ 2.43	7.74	\$ 86
Shares reserved for issuance				
Options granted	3,646,290	\$ 1.53		
Options exercised	—	\$ —		
<b>Balances at March 31, 2026 (unaudited)</b>	<u>15,636,978</u>	<u>\$ 2.22</u>	8.06	\$ 83
<b>At March 31, 2026</b>				
Vested and expected to vest	<u>15,636,978</u>	\$ 2.22	8.06	\$ 83
Exercisable	<u>6,138,335</u>	\$ 3.35	6.49	\$ —

At March 31, 2026, the total compensation cost related to nonvested awards not yet recognized was \$13,701. The weighted-average period over which the nonvested awards is expected to be recognized was 2.9 years.

The Company estimated the fair value of the options using the Black-Scholes options valuation model. The fair value of the options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value was estimated using the following assumptions:

	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Risk-free interest rate	3.82%	4.02% - 4.48%
Expected life (in years)	6.02	6.02 - 6.25
Dividend yield	0%	0%
Expected volatility	77.29%	80.22%

The weighted average assumptions used to estimate the fair value of stock purchase rights under the 2020 ESPP are as follows:

	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Risk-free interest rate	3.70%	4.28%
Expected life (in years)	0.49	0.49
Dividend yield	0%	0%
Expected volatility	78.28%	82.05%

**Risk Free Interest Rate:** The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.

**Expected Term:** The Company uses the simplified method to calculate expected term described in the SEC's Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.

**Dividend Yield:** The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

**Volatility:** Volatility is based on the historical volatility of the Company's publicly traded shares for the expected term.

***Restricted Stock Units***

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

For the quarter ending March 31, 2026, no RSU awards were granted, vested, or unvested. As of March 31, 2026, there was no unrecognized compensation cost related to RSUs that are expected to vest.

Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2020 ESPP were allocated to research and development and general and administrative expense as follows:

	For the Three Months Ended	
	March 31, 2026	March 31, 2025
Research and development	\$ 637	\$ 637
General and administrative	755	871
Total stock-based compensation	\$ 1,392	\$ 1,508

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

	For the Three Months Ended	
	March 31, 2026	March 31, 2025
Stock options	\$ 1,359	\$ 1,149
Restricted stock units	—	278
Employee stock purchase plan	33	81
Total stock-based compensation	\$ 1,392	\$ 1,508

#### 9. Income Taxes

The Company's effective tax rates were 0% and 11% for the three months ended March 31, 2026 and 2025, respectively. The income tax provision and effective tax rate are driven primarily by the proceeds from the sale of the Company's New Jersey tax net operating loss carryforwards and research and development ("R&D") tax credits received in 2024 and 2025.

During the three months ended March 31, 2026 and 2025, the Company recorded a full valuation allowance on federal and state net deferred tax assets since management does not forecast the Company to be in a taxable position in the near future.

The State of New Jersey's Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell unused net-operating loss ("NOL") carryforwards and R&D tax credits to other New Jersey-based corporate taxpayers. For the three months ended March 31, 2025, we received a benefit for income taxes of \$2,196. As of March 31, 2025, the Company received \$18,372 of cash for the NOL and R&D tax credit sales related to the tax years ended December 31, 2015 to 2023. For the three months ended March 31, 2026, the Company did not receive any benefit for income taxes.

#### 10. Net Loss per Share

The Company excluded all outstanding stock options and RSUs at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. The following common stock equivalents were excluded from the calculation of diluted net loss per share:

	March 31, 2026	March 31, 2025
Options to purchase common stock	15,636,978	11,947,135
Unvested restricted stock units	—	907,666
Expected shares to be purchased under 2020 ESPP	20,241	18,898
Total	15,657,219	12,873,699

**PMV Pharmaceuticals, Inc.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**  
**(in thousands, except share and per share amounts)**

**11. Related Parties**

The Company has consulting agreements with three members of its board of directors; one of which waived his consulting fees starting as of September 2021. Total consulting fees paid during the three months ended March 31, 2026 and 2025 were \$30 and \$50, respectively. There were no amounts owed under the consulting agreements as of March 31, 2026.

**12. Segment Information**

The Company has viewed its operations and manages its business as one operating and reporting segment. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company's chief operating decision maker ("CODM") to make decisions with respect to resource allocation and assessment of performance. The Company's CODM is its Chief Executive Officer (the "CEO"), who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO.

The CEO regularly reviews the condensed consolidated statement of operations and a disaggregation of operating expenses, of which the significant expenses are related to research and development. The following table represents the significant segment expenses regularly provided to the CEO:

	For the Three Months Ended	
	March 31, 2026	March 31, 2025
Research and Development		
Research	\$ 1,058	\$ 1,283
Development	9,690	11,951
Personnel related	3,945	3,570
Stock-based compensation	637	637
Total research and development	15,330	\$ 17,441
General and administrative		
Personnel related	\$ 1,513	\$ 1,479
Stock-based compensation	755	871
External	1,421	1,773
Total general and administrative	3,689	4,123
Loss from Operations	\$ 19,019	\$ 21,564

**13. Subsequent Event**

The Company has evaluated subsequent events through May 12, 2026, the date these financial statements were issued. The Company determined that there were no subsequent events that required adjustment to or disclosure in the financial statements.

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

*You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q and our audited condensed consolidated financial statements and notes thereto as of and for the years ended December 31, 2025 and 2024 and the related “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including “Contractual Obligations and Commitments” and “Critical Accounting Policies and Estimates,” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission, or the SEC, on March 6, 2026. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to PMV Pharmaceuticals, Inc.*

*In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to those set forth under the captions “Special Note Regarding Forward-Looking Statements,” “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended. Furthermore, past operating results are not necessarily indicative of results that may occur in future periods.*

### Overview

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target p53 mutations and other p53-related cancers.

Since our formation in March 2013, we have devoted substantially all of our time and efforts to performing research and development activities and raising capital. We are not profitable and have incurred losses in each year since our inception. During the three months ended March 31, 2026, we incurred net losses of \$18.0 million. As of March 31, 2026, we had an accumulated deficit of \$464.5 million. We do not currently have any product candidates approved for sale, and we continue to incur significant research and development and general and administrative expenses related to our operations. We initiated a Phase 1/2 clinical trial, PYNACLE, in October 2020 for our lead product candidate, rezatapopt. Our strategy is to seek approval under an accelerated pathway, and we believe the Phase 2 portion of the PYNACLE clinical trial has the potential to serve as a pivotal study. In October 2020, we were granted FDA Fast Track designation of rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. In July 2023, we met with the FDA at an End of Phase 1 meeting where alignment was obtained on the recommended Phase 2 dose and key elements of the single arm, Phase 2 registrational portion of the PYNACLE study. In October 2023, we presented our updated Phase 1 clinical data for rezatapopt at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting. We dosed our first patient in the pivotal Phase 2 monotherapy portion of the PYNACLE study in the first quarter of 2024. In September 2025, we announced interim data from the Phase 2 pivotal portion of the PYNACLE clinical trial, which was updated in October 2025 in a late-breaking oral presentation and poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. In March 2026, rezatapopt was granted Orphan Drug Designation, or ODD, from the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. We plan to submit a New Drug Application, or NDA, for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation to the FDA for rezatapopt in the first quarter of 2027.

We expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization; acquire, discover, validate, and develop additional product candidates; obtain, maintain, protect, and enforce our intellectual property portfolio; and hire additional personnel. We expect to continue to incur significant losses for the foreseeable future.

Our ability to generate product revenue will depend on the successful development, regulatory approval, and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates.

We plan to continue to use third-party service providers, including clinical research organizations, or CROs, and contract manufacturing organizations, or CMOs, to carry out our preclinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. We do not currently have a sales force.

## **Components of Results of Operations**

### ***Revenue***

To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or result in license agreements with third parties, we may generate revenue in the future from product sales or license agreements. However, there can be no assurance as to when we will generate such revenue, if at all.

### ***Operating Expenses***

#### ***Research and Development Expenses***

Our research and development expenses consist primarily of costs incurred to conduct research, such as the discovery and development of our product candidates as well as the development of future product candidates. Research and development expenses include personnel costs, including stock-based compensation expense, third-party contractor services, laboratory materials and supplies, and depreciation and maintenance of research equipment. We expense research and development costs as they are incurred.

We do not allocate our costs by product candidate or development program, as a significant amount of research and development expenses include compensation costs, materials, supplies, depreciation on and maintenance of research equipment, and the cost of services provided by outside contractors, which are not tracked by product candidate or development program. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. Substantially all of our research and development costs are associated with our lead product candidate, rezatapopt. We initiated our Phase 1/2 PYNNAACLE clinical trial in October 2020, and on that date, we were granted FDA Fast Track designation of rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. In October 2023, we presented our updated Phase 1 clinical data for rezatapopt at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. In September 2025, we announced interim data from the Phase 2 pivotal portion of the PYNNAACLE clinical trial, which was updated in October 2025 in a late-breaking oral presentation and poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. In March 2026, rezatapopt was granted ODD from the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. We plan to submit an NDA for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation to the FDA for rezatapopt in the first quarter of 2027.

We expect to continue to incur substantial research and development expenses in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, clinical data, investment in our clinical program, the ability of any future collaborators to successfully develop our licensed product candidates, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects.

### ***General and Administrative Expenses***

General and administrative expenses include personnel costs, expenses for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facilities. We have incurred expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase our general and administrative expenses as we advance our product candidates through preclinical research and development, manufacturing, clinical development, and commercialization.

### ***Interest Income, Net***

Interest income, net, primarily consists of interest income from our interest-bearing cash, cash equivalents, and marketable securities, and interest costs related to accretion and amortization of discounts and premiums on marketable securities.

## **Results of Operations**

### ***Comparison of the Three Months Ended March 31, 2026 and 2025***

The following table summarizes our results of operations (in thousands):

<b>Statement of operations data:</b>	<b>For the Three Months Ended</b>		<b>Change</b>
	<b>March 31, 2026 (Unaudited)</b>	<b>March 31, 2025 (Unaudited)</b>	
Operating expenses:			
Research and development	\$ 15,330	\$ 17,441	\$ (2,111)
General and administrative	3,689	4,123	(434)
Total operating expenses	19,019	21,564	(2,545)
Loss from operations	(19,019)	(21,564)	2,545
Other income (expense):			
Interest income, net	980	1,935	(955)
Other income (expense), net	1	(4)	5
Total other income (expense)	981	1,931	(950)
Loss before (benefit) provision for income taxes	(18,038)	(19,633)	1,595
(Benefit) provision for income taxes	—	(2,197)	2,197
Net loss	<u>\$ (18,038)</u>	<u>\$ (17,436)</u>	<u>\$ (602)</u>

### **Research and Development Expenses**

The following table summarizes our research and development expenses incurred during the periods indicated (in thousands):

Statement of operations data:	For the Three Months Ended		Change
	March 31, 2026	March 31, 2025	
	(Unaudited)	(Unaudited)	
Research	\$ 1,058	\$ 1,283	\$ (225)
Development	9,690	11,951	(2,261)
Personnel related	3,945	3,570	375
Stock-based compensation	637	637	—
<b>Total</b>	<b>\$ 15,330</b>	<b>\$ 17,441</b>	<b>\$ (2,111)</b>

Research and development expenses were \$15.3 million for the three months ended March 31, 2026, compared to \$17.4 million for the three months ended March 31, 2025. The decrease of \$2.1 million, compared to the three months ended March 31, 2025, was primarily due to the following:

- \$2.5 million decrease in research and development expenses largely driven by decreased contractual research organization costs for advancing our lead product candidate, rezatapopt; offset by
- \$0.4 million increase in personnel related costs.

### **General and Administrative Expenses**

General and administrative expenses were \$3.7 million for the three months ended March 31, 2026, compared to \$4.1 million for the three months ended March 31, 2025. The decrease of \$0.4 million, compared to the three months ended March 31, 2025, was primarily due to a \$0.1 million decrease in personnel expenses and a \$0.3 million decrease in finance and legal support costs.

### **Interest Income, Net**

Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents, and marketable securities and interest costs related to accretion and amortization of discounts and premiums on marketable securities. Interest income, net was \$1.0 million for the three months ended March 31, 2026, compared to \$1.9 million for the three months ended March 31, 2025. The decrease of \$0.9 million compared to the three months ended March 31, 2025 was driven by a decline in interest rates combined with lower overall balances in interest-bearing cash, cash equivalents, and investments in marketable securities during the three months ended March 31, 2026.

### **Income Tax Benefit**

The State of New Jersey's Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell NOL carryforwards and R&D tax credits to other New Jersey-based corporate taxpayers. As of March 31, 2025, we received \$18.4 million of cash for the NOL and R&D tax credit sales related to the tax years ended December 31, 2015 to 2023. The sale of the NOLs and R&D tax credits have been recorded as an income tax benefit within the condensed consolidated statement of operations. For the three months ended March 31, 2025, we had reached the sale limit established by the program and received a benefit for income taxes of \$2.2 million. We did not receive any benefit for income taxes for the three months ended March 31, 2026.

## Liquidity and Capital Resources

Our financial condition is summarized as follows (in thousands):

	As of March 31, 2026	As of December 31, 2025	Change
<b>Financial assets:</b>			
Cash and cash equivalents	\$ 39,130	\$ 37,983	\$ 1,147
Marketable securities – current	54,419	74,960	(20,541)
Marketable securities – noncurrent	—	—	—
<b>Total financial assets</b>	<b>\$ 93,549</b>	<b>\$ 112,943</b>	<b>\$ (19,394)</b>
<b>Working capital:</b>			
Current assets	\$ 95,780	\$ 115,227	\$ (19,447)
Current liabilities	8,595	11,415	(2,820)
<b>Total working capital</b>	<b>\$ 87,185</b>	<b>\$ 103,812</b>	<b>\$ (16,627)</b>

### *Sources of Liquidity*

Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates. Even if the Company's drug development and commercialization efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. As of March 31, 2026, we had cash, cash equivalents, and marketable securities of \$93.5 million and an accumulated deficit of \$464.5 million. We have financed our operations primarily through issuance and sales of our equity securities.

On November 20, 2024 we filed a shelf registration statement on Form S-3 (File No. 333-283349) with the SEC and a prospectus supplement, which registered the offering, issuance and sale of up to \$200.0 million of various equity and debt securities and up to \$113.8 million of common stock pursuant to an at-the-market equity offering program with Jefferies LLC, dated October 4, 2021, or the ATM Program. The SEC declared the registration statement effective on November 27, 2024. During the three months ending March 31, 2026, we did not sell any shares of our common stock pursuant to the ATM Program. As of March 31, 2026, we had approximately \$113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

### *Contractual Obligations and Commitments*

We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts.

In September 2024, we signed two subleases, one for 14,201 square feet of office space at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey, to be used as our new headquarters, or the 400 Alexander Sublease, and the other for 3,205 square feet of office and laboratory space at 311 Pennington Rocky Hill in Hopewell, New Jersey, to be used for our new laboratory space, or the 311 Pennington Sublease. The 400 Alexander Sublease term extends until February 2027. Amounts related to future lease payments for the 400 Alexander Sublease as of March 31, 2026, totaled \$0.3 million with \$0.3 million to be paid within the next 12 months. In March 2026, the 311 Pennington Sublease was terminated by the sublessor and we recorded a net gain of approximately \$24, which was recognized in General and Administrative expense.

### *Plan of Operation and Future Funding Requirements*

We use our capital resources primarily to fund operating expenses, mainly research and development expenditures. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval and commercialize our current product candidates or any future product candidates, if at all. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Due to our significant research and development expenditures, we have generated substantial operating losses in each period since inception. We have incurred an accumulated deficit of \$464.5 million through March 31, 2026. We expect to incur substantial additional losses in the future. For the three months ended March 31, 2026 and 2025, our cash operating expenditures were \$19.7 million and \$18.3 million, respectively. Based on our research and development plans, we expect that our cash, cash equivalents, and marketable securities as of March 31, 2026 will be sufficient to fund our planned operations until the end of the second quarter of 2027.

We have based this estimate on assumptions that may prove to be wrong, however, and we could use our capital resources sooner than we expect.

The timing and amount of our operating expenditures will depend largely on:

- the timing and progress of preclinical and clinical development activities;
- the number and scope of preclinical and clinical programs we decide to pursue;
- the timing and amount of milestone payments we may receive under any future collaboration agreements;
- our ability to maintain future licenses and research and development programs and to establish new collaboration and/or in-licensing arrangements;
- the costs involved in prosecuting and enforcing patent and other intellectual property claims;
- the cost and timing of regulatory approvals; and
- our efforts to manage our office and laboratory headquarters, enhance operational systems and hire additional personnel to support development of our product candidates and satisfy our obligations as a public company.

Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations and prospects.

### **Cash Flows**

The following table summarizes our cash flows for the period indicated (in thousands):

	For the Three Months Ended	
	March 31, 2026 (Unaudited)	March 31, 2025 (Unaudited)
Cash used in operating activities	\$ (19,679)	\$ (18,266)
Cash provided by investing activities	20,824	28,714
Cash provided by financing activities	—	10
Impact of exchange rates on cash, cash equivalents, and restricted cash	2	7
Net increase in cash and cash equivalents	<u>\$ 1,147</u>	<u>\$ 10,465</u>

### **Operating Activities**

Net cash used in operating activities for the three months ended March 31, 2026, was \$19.7 million, which consisted primarily of net loss of \$18.0 million, partially offset by non-cash charges of \$1.0 million. Changes in our net operating assets decreased operating cash by \$2.7 million. The non-cash charges primarily consisted of stock-based compensation of \$1.4

million, and accretion of discounts on marketable securities of \$0.4 million. The change in our net operating assets and liabilities was primarily due to a decrease in outstanding payables and accrued expenses.

Net cash used in operating activities for the three months ended March 31, 2025, was \$18.3 million, which consisted primarily of net loss of \$17.4 million partially offset by non-cash charges of \$0.7 million. Changes in our net operating assets decreased operating cash by \$1.5 million. The non-cash charges primarily consisted of stock-based compensation of \$1.5 million, and accretion of discounts on marketable securities of \$0.8 million. The change in our net operating assets and liabilities was primarily due to a decrease in prepaid expenses and other assets, an increase in outstanding payables and a decrease in accrued expenses.

### ***Investing Activities***

Our investing activities provided \$20.8 million of cash during the three months ended March 31, 2026, which consisted primarily of maturities of marketable securities of \$31.5 million, partially offset by purchases of marketable securities of \$10.7 million.

Our investing activities provided \$28.7 million of cash during the three months ended March 31, 2025, which consisted primarily of maturities of marketable securities of \$44.4 million, partially offset by purchases of marketable securities of \$15.7 million.

### ***Financing Activities***

For the three months ended March 31, 2026 and 2025, net cash provided by financing activities was zero.

## **Critical Accounting Policies and Estimates**

The preparation of our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the amounts reported in those condensed consolidated financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results reported in future periods could differ from those estimates.

We believe that the accounting policies described below involve a high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of our operations. During the three-month period ended March 31, 2026, there were no material changes to our critical accounting policies from those described in our audited condensed consolidated financial statements for the year ended December 31, 2025, included in our Annual Report on Form 10-K filed with the SEC on March 6, 2026, except as noted below.

### ***Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses***

Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including sourcing of raw materials and manufacturing of our product candidates, allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development advance payments are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or services are performed.

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:

- vendors, including research laboratories, in connection with preclinical development activities;
- CROs and investigative sites in connection with preclinical studies and clinical trials; and

- CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.

We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

### **Recent Accounting Pronouncements**

For a description of recent accounting pronouncements, see Note 2 of the notes to our unaudited condensed consolidated financial statements for the three months ended March 31, 2026 included elsewhere in this Quarterly Report on Form 10-Q.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks.

We had cash, cash equivalents, and marketable securities of \$93.5 million as of March 31, 2026. The Company's cash equivalents consist of interest-bearing U.S. treasury securities, money market funds, and corporate debt securities. Our exposure due to changes in interest rates is not material due to the nature and amount of our money-market funds and marketable securities.

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we may contract with foreign vendors that are located outside the United States in the future. This may subject us to fluctuations in foreign currency exchange rates in the future.

### **Item 4. Controls and Procedures.**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Securities Exchange Act of 1934, as amended, reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

We carry out a variety of ongoing procedures, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, to evaluate the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2026.

There have not been any changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II—OTHER INFORMATION

### Item 1. Legal Proceedings.

We are not currently involved in any litigation or legal proceedings that, in management's opinion, are likely to have any material adverse effect on the Company.

### Item 1A. Risk Factors.

There have been no material changes to the Company's risk factors as set forth in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on March 6, 2026, which are hereby incorporated by reference. You should carefully review and consider the information regarding such risk factors and the risks and uncertainties described elsewhere in this report which could materially affect our business, financial condition or future prospects.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

#### *(a) Unregistered Sales of Equity Securities*

None.

#### *(b) Use of Proceeds*

Our initial public offering of our common stock was effected pursuant to a registration statement on Form S-1 (File No. 333-248627), which was declared effective by the SEC on September 24, 2020. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020.

#### *(c) Issuer Purchases of Equity Securities.*

None.

### Item 3. Defaults Upon Senior Securities.

None.

### Item 4. Mine Safety Disclosures.

Not applicable.

### Item 5. Other Information.

Not applicable.

**Item 6. Exhibits.**

Exhibit Number	Description	Form	File No.	Number	Filing Date
3.1	<a href="#">Amended and Restated Certificate of Incorporation of the Registrant.</a>	8-K	001-39539	3.1	September 29, 2020
3.2	<a href="#">Amended and Restated Bylaws of the Registrant.</a>	10-Q	001-39539	3.3	May 10, 2023
31.1+	<a href="#">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				
31.2+	<a href="#">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				
32.1+†	<a href="#">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				
32.2+†	<a href="#">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				
101.INS	Inline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.				
101.SCH	Inline XBRL Taxonomy Extension Schema Document.				
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).				

† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

+ Filed herewith.







**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q for the period ended March 31, 2026, of PMV Pharmaceuticals, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2026

By: \_\_\_\_\_  
/s/ David H. Mack  
**David H. Mack, Ph.D.**  
**Chief Executive Officer**  
**(Principal Executive Officer)**

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q for the period ended March 31, 2026, of PMV Pharmaceuticals, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2026

By: \_\_\_\_\_  
/s/ Michael Carulli  
**Michael Carulli**  
**Chief Financial Officer**  
**(Principal Financial and Accounting Officer)**

---

